Journal article
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial
Abstract
This study evaluated the benefits of ZOL versus placebo on health-related quality of life (HRQoL) among patients from HORIZON–RFT. At month 24 and end of the study visit, ZOL significantly improved patients’ overall health state compared to placebo as assessed by the EQ-5D VAS.IntroductionTo evaluate the benefits of zoledronic acid (ZOL) versus placebo on health-related quality of life (HRQoL) among patients from The Health Outcomes and Reduced …
Authors
Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA
Journal
Osteoporosis International, Vol. 22, No. 9, pp. 2539–2549
Publisher
Springer Nature
Publication Date
September 2011
DOI
10.1007/s00198-010-1514-9
ISSN
0937-941X